The invitation only meeting on May 6-9, 2018 boasts an outstanding scientific programme and will take place in a beautiful location and inspiring atmosphere. We have invited international experts to complement the scientific programme of the two SFBs, including: Jacqueline Bromberg, New York; Gerard Evan, Cambridge; Thomas Graf, Barcelona; Nancy Hynes, Basel; Shai Izraeli, Tel Aviv; David Levy, New York; A. Tom Look, Harvard;  Tak Mak, Toronto

A cooperation of Ludwig Boltzmann Institute for Cancer Research, Ludwig Boltzmann Cluster Oncology, SFB-F47, and SFB-F61

Figure: The meeting will be held at Seggau Castle in Styria, close to the city of Leibnitz

Acute myeloid leukaemia (AML) is the most common type of acute cancer of the blood and bone marrow in adults. This type of cancer usually progresses quickly and only 26 percent of the patients survive longer than 5 years as resistance against established treatments arises. The most common molecular cause is FLT3 mutations, which result in hyper-activation of STAT5. An international consortium of researchers cofounded by SFB-F61 now report on an early preclinical development to target STAT5 directly, which cooperates well with existing therapies.

Publication in Leukemia:

Bettina Wingelhofer, Barbara Maurer, Elizabeth C. Heyes, Abbarna C. Cumaraswamy, Angelika Berger-Becvar, Elvin D. de Araujo, Anna Orlova, Patricia Freund, Frank Ruge, Jisung Park, Gary Tin, Siawash Ahmar, Charles-Hugues Lardeau, Irina Sadovnik, Dávid Bajusz, György Miklós Keserű, Florian Grebien, Stefan Kubicek, Peter Valent, Patrick T. Gunning and Richard Moriggl,

Pharmacologic inhibition of STAT5 in acute myeloid leukemia, Leukemia (2018), doi:10.1038/s41375-017-0005-9

Figure: Schematic representation of the STAT5 Inhibitor mapped onto the SH2-domain of STAT5